Under the terms of the deal, Beijing-based GeneCast has the exclusive right to market Agendia's MammaPrint and BluePrint tests to Chinese customers.
The company has struck a deal to market its tests, including ones based on its Aristotle early cancer detection platform, in collaboration with LifeX.
Dian selected the MassArray system as its platform of choice for molecular genetic testing and will commercialize it and Agena's DNA applications and products.
The companion diagnostic test identifies patients taking the Novartis drug Tasigna who are candidates for treatment-free remission monitoring.
The deals cover Plexbio's IntelliPlex 1000 πCode Processor and the PlexBio 100 Fluorescent Analyzer for the IVD and life science research markets.
The five CROs will be able to offer DSP analyses to their customers through a technology access program ahead of NanoString's planned platform launch in 2019.
The companies will comarket Clearbridge's ClearCell CTC system and Leica's Bond Rx staining platform.
Promega's technology will be part of a larger portfolio of research products aimed at supporting oncology drug and clinical trial development.
AmCare Genomics said that it has a large network that would enable it to raise awareness about Genomic Vision's test for facioscapulohumeral muscular dystrophy.
Thermo Fisher will sell Synthego's synthetic guide RNA products under the Invitrogen TrueGuide brand.
GenomeWeb reports that Veritas Genetics is suspending its US operations.
A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.
Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.
In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.